Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Alemtuzumab 12 mg vs interferon beta‐1a

Relapse · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 12 mg probably leads to lower number of participants experiencing at least one relapse compared with interferon beta 1a (moderate certainty).

1 finding from 1 review

alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis 2017 · Cochrane Headline outcomes only
RR 0.6 [0.52, 0.7]
3 studies · 1414 participants
Moderate

Alemtuzumab 24 mg vs interferon beta‐1a

Relapse · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 24 mg may leads to lower number of participants experiencing at least one relapse compared with interferon beta 1a (low certainty).

1 finding from 1 review

alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis 2017 · Cochrane Headline outcomes only
RR 0.38 [0.23, 0.62]
1 study · 221 participants
Low